Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Using human glioma cell line U251, biological responses of glioma cells to combination usage of angiogenesis inhibitor (bevacizumab) and chemotherapeutic agent (rapamycin) was investigated in vitro and in vivo. The result of this study suggested that the growth of glioma might be inhibited by rapamycin,which blocked the secondary angiogenesis, resulted from hypoxic state by bevacizumab. Thus, this type of concomitant therapy could be one of the novel approaches of malignant glioma.
|